Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) found itself under scrutiny back in 2024 when Kahn Swick & Foti, LLC began investigating its officers and directors for possible breaches of fiduciary duty. The firm wasn't just casting a casual glance; they were diving deep into whether Verrica's leadership might have skirted state or federal laws while failing their shareholders.
FDA Approval Woes: What Went Down?
This all came after years of hype around Verrica’s lead product, VP-102, which was positioned to tackle molluscum contagiosum—a viral skin infection that had baffled treatments for ages. They threw their hat in the ring with the FDA back in December 2020 with a New Drug Application (NDA). But things took a nosedive.
- Complete Response Letters: In September 2021, the company received a Complete Response Letter from the FDA citing manufacturing deficiencies at one of its contract facilities. Another letter dropped in May 2022, reiterating further issues with manufacturing standards. Each setback sent waves through investor confidence.
You see, every time an FDA roadblock pops up, investors start scrambling like it's a fire drill—no one wants to hold shares when approval feels like chasing rainbows. The stock typically gets pummeled on news like that, and it wasn’t long before those bearish sentiments hit Verrica hard.
Securities Class Action: A Major Legal Storm
Fast forward to the fallout: shareholders banded together to launch a securities class action lawsuit against Verrica and select executives. Their beef? Allegations that top brass didn’t disclose critical info during this tumultuous period—the kind of stuff that could sink ships faster than you can say 'breach of trust.' The court's response was not pretty for the company; they denied motions to dismiss these charges, allowing everything to roll ahead toward trial.
